Rybelsus (Oral Semaglutide) in Adolescents Ages 12 to 17: Off-Label Use Explained

Why Rybelsus Is Not Approved for Adolescents

Rybelsus received FDA approval in September 2019 for glycemic control in adults with type 2 diabetes at doses of 7 mg and 14 mg daily. The approval was based on the PIONEER clinical program, which enrolled only adults. No pediatric indication has been granted, and the FDA label explicitly states use in patients under 18 has not been established.

The PIONEER Program and Its Adult-Only Enrollment

The PIONEER program comprised ten trials enrolling a combined total of over 9,500 adult participants across PIONEER 1 through 10. PIONEER 1 (N=703) demonstrated that oral semaglutide 14 mg reduced HbA1c by 1.5 percentage points versus placebo at 26 weeks [1]. PIONEER 6 (N=3,183) was the cardiovascular outcomes trial and again enrolled adults exclusively, showing non-inferiority for major adverse cardiovascular events versus placebo [2].

Because none of these trials included adolescents, the FDA has no pediatric efficacy or safety dataset for oral semaglutide on which to base an approval.

What the FDA Pediatric Research Equity Act Requires

Under the Pediatric Research Equity Act (PREA), manufacturers must conduct pediatric studies for drugs likely to be used in children unless a waiver or deferral is granted. Novo Nordisk has received a deferral for Rybelsus in the pediatric population while adult development was completed. As of July 2025, no phase 3 pediatric trial results for oral semaglutide in ages 12 to 17 have been published or posted to ClinicalTrials.gov with a completion date [3].

Injectable Semaglutide in Adolescents: The Approved Alternatives

Understanding what injectable semaglutide can do in adolescents is essential context for any discussion of the oral form. The two formulations share the same active molecule but differ substantially in absorption, dosing, and clinical data.

STEP TEENS: The Wegovy Adolescent Trial

The STEP TEENS trial (N=201, ages 12 to 17, BMI at or above the 95th percentile) is the definitive dataset. Participants received subcutaneous semaglutide 2.4 mg weekly or placebo for 68 weeks alongside lifestyle intervention. The semaglutide group achieved a 16.1% reduction in BMI versus a 0.6% reduction in the placebo group (P<0.001) [4]. Roughly 45% of adolescents on semaglutide lost at least 20% of their body weight. Gastrointestinal adverse events (nausea, vomiting, diarrhea) were the most common reasons for discontinuation.

The New England Journal of Medicine published STEP TEENS in 2022, and the FDA approved Wegovy for adolescents 12 and older with obesity in June 2022 based substantially on this data [5].

Ozempic Approval in Pediatric Type 2 Diabetes

Ozempic (subcutaneous semaglutide 0.5 mg and 1 mg weekly) received an expanded approval in May 2022 for patients as young as 10 years with type 2 diabetes [6]. That approval was supported by the ELLIPSE trial (N=131, ages 10 to 17), where semaglutide 1 mg weekly reduced HbA1c by 1.4 percentage points versus placebo at 26 weeks [7].

The ELLIPSE data matters here: it is the closest we have to a controlled semaglutide efficacy signal in the 12 to 17 age bracket, even though it used the injectable form.

Why Oral Bioavailability Complicates Adolescent Extrapolation

Oral semaglutide relies on co-formulation with sodium N-(8-(2-hydroxybenzoyl)amino)caprylate (SNAC) to survive gastric acid and cross the gastric mucosa. Even optimally administered, bioavailability is roughly 1% compared with approximately 89% for the subcutaneous form [8].

Administration Requirements That Adolescents May Find Difficult

Adults taking Rybelsus must swallow the tablet with no more than 4 oz (120 mL) of plain water, at least 30 minutes before any food, drink, or other medication. Deviation from this protocol meaningfully reduces absorption. A 2019 pharmacokinetic analysis published in the journal Clinical Pharmacology and Therapeutics confirmed that taking Rybelsus with a standard breakfast reduced semaglutide AUC by approximately 40% [9].

For adolescents, adherence to a fasting administration window each morning before school, sports, or other activity is a real-world barrier that clinicians should discuss explicitly with families.

Dose Exposure Differences Between Adults and Adolescents

No published pharmacokinetic study has characterized oral semaglutide exposure specifically in adolescents ages 12 to 17. Body weight, gastric acid secretion, and gastrointestinal transit time all differ between adults and adolescents, and these factors influence SNAC-facilitated absorption. Prescribers extrapolating from adult PK data are working without a validated model for this age group.

The Case for Off-Label Prescribing in Certain Adolescents

Off-label prescribing is legal in the United States and common in pediatric medicine. The American Academy of Pediatrics has noted that up to 80% of drugs used in children carry some off-label designation, given the historical underrepresentation of pediatric patients in clinical trials [10].

Situations Where Off-Label Rybelsus May Be Considered

Clinicians at academic pediatric centers have used Rybelsus off-label in specific scenarios where injectable semaglutide is not an option. Common rationales include:

• Needle phobia severe enough to preclude subcutaneous injection despite behavioral support
• Prior allergic or injection-site reactions to the subcutaneous formulation
• Patient or family preference for an oral medication after full informed consent discussion
• Insurance coverage structures in which oral agents are covered but injectables are not

None of these rationales override the absence of pediatric safety data. Each case requires individual clinical judgment.

What Pediatric Endocrinology Guidelines Say

The American Diabetes Association's 2024 Standards of Care state that for youth with type 2 diabetes, liraglutide (injectable, approved for ages 10+) and semaglutide (injectable, approved for ages 10+) are preferred GLP-1 options when GLP-1 therapy is indicated [11]. The Standards do not endorse oral semaglutide in pediatric patients. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy in adolescents similarly lists only approved agents [12].

Clinicians considering off-label Rybelsus should document: the reason injectable semaglutide is not being used, the clinical indication, the absence of pediatric approval, a discussion of unknown pediatric-specific risks, and signed informed consent from both the patient (if mature minor status applies) and the legal guardian.

Potential Risks Specific to the Adolescent Population

Several adverse-effect categories warrant heightened attention in patients ages 12 to 17.

Bone Mineral Density and Linear Growth

Adolescence is the period of peak bone mineral accrual and the final phase of linear growth for most patients. GLP-1 receptors are expressed in osteoblasts, and preclinical data suggest GLP-1 agonism may have direct effects on bone metabolism, though the direction and clinical magnitude remain uncertain [13]. No long-term bone density data exist for oral semaglutide in adolescents. Prescribers should obtain baseline and annual dual-energy X-ray absorptiometry (DXA) scans and track height at every visit.

Gastrointestinal Tolerability

Nausea and vomiting are the most frequently reported adverse events with oral semaglutide across the PIONEER trials, occurring in roughly 20% of adult participants on 14 mg [1]. In the STEP TEENS injectable trial, GI events led to discontinuation in approximately 4% of adolescents [4]. Because the oral route bypasses the systemic absorption advantages of the injection and relies on high local gastric concentrations of SNAC, some clinicians hypothesize GI tolerability may differ. No comparative data exist.

Thyroid C-Cell Risk and Family History

The Rybelsus prescribing information carries a black-box warning for thyroid C-cell tumors based on rodent carcinogenicity studies. The FDA has not established this risk in humans, but the label contraindicates use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [14]. This warning applies equally to adolescent patients.

Eating Disorder Screening

Adolescents have higher rates of disordered eating than adults. The appetite suppression associated with GLP-1 receptor agonists could interact with existing restrictive eating behaviors or contribute to unhealthy weight-loss practices. The Endocrine Society recommends screening for eating disorders before initiating weight-loss pharmacotherapy in adolescents [12]. Tools such as the SCOFF questionnaire or the Eating Attitudes Test-26 should be part of the pre-treatment evaluation.

Practical Dosing Framework If Off-Label Use Is Elected

Adult dosing for Rybelsus starts at 3 mg once daily for 30 days to improve gastrointestinal tolerability, then advances to 7 mg for at least 30 days, then optionally to 14 mg for additional glycemic or weight effect. The FDA-approved adult label specifies this titration schedule [14].

No Validated Adolescent Dose Has Been Established

Because no pediatric PK study exists, pediatric endocrinologists who elect to use Rybelsus off-label typically follow the adult titration schedule, starting at 3 mg and advancing based on individual tolerability. Some clinicians remain at 7 mg rather than advancing to 14 mg given the lack of adolescent data. This is a clinical decision made without supporting trial evidence and should be communicated clearly to families.

Administration Counseling for Adolescent Patients

Concrete instructions matter. The tablet must be taken:

• On an empty stomach, first thing in the morning
• With no more than 4 oz of plain water
• At least 30 minutes before eating, drinking anything other than water, or taking other oral medications
• Swallowed whole, not chewed, crushed, or split

A study by Buckley et al. (2018) published in Clinical Pharmacology and Therapeutics showed that splitting or crushing the tablet eliminated the SNAC-facilitated absorption mechanism entirely [9]. School nurses, coaches, and caregivers involved in an adolescent's morning routine should be made aware of these requirements.

Monitoring Protocol for Adolescents on Off-Label Rybelsus

Given the absence of pediatric trial data, monitoring should be more frequent than in adults and should capture growth parameters that are irrelevant in adult care.

Baseline Assessment

Before starting oral semaglutide in a 12 to 17-year-old, clinicians should obtain:

• Height, weight, and BMI with plotting on pediatric growth curves
• HbA1c and fasting glucose
• Fasting lipid panel
• Liver function tests and serum lipase
• Thyroid function (TSH, free T4)
• DXA scan if the patient has additional risk factors for low bone density
• SCOFF or EAT-26 eating disorder screening
• Depression and anxiety screening (PHQ-A for adolescents)

Follow-Up Schedule

Monthly visits for the first three months allow early detection of GI adverse events and assessment of absorption-related issues. After dose stabilization, visits every three months are reasonable, with annual laboratory reassessment. Height should be measured at every visit through age 18 or until growth plates close.

Insurance Coverage and Access Barriers for Adolescents

Rybelsus carries a list price of approximately $936 per month as of 2025 for the 14 mg dose. Insurance coverage for off-label pediatric use is inconsistent. Many commercial plans require prior authorization with documentation of the off-label rationale and failure of first-line agents. Medicaid coverage varies by state.

Novo Nordisk offers a savings card program for commercially insured adult patients, but eligibility criteria for patients under 18 are not clearly established in program documentation. Families should verify coverage before initiating a prescription. The absence of a pediatric approval makes formulary access more difficult than for injectable alternatives that carry approved pediatric indications.

Comparing Oral Semaglutide to Injectable Alternatives in Adolescents

When an adolescent with obesity or type 2 diabetes is a candidate for semaglutide therapy, the injectable forms are the evidence-based first choice.

| Feature | Rybelsus (oral) | Wegovy (injectable) | Ozempic (injectable) | |---|---|---|---| | FDA-approved age <18 | No | Yes, 12+ (obesity) | Yes, 10+ (type 2 DM) | | Pediatric trial data | None published | STEP TEENS (N=201) | ELLIPSE (N=131) | | Bioavailability | ~1% | ~89% | ~89% | | Dosing frequency | Daily | Weekly | Weekly | | Administration complexity | High (fasting protocol) | Low (inject any time) | Low (inject any time) | | GI adverse events (adult data) | ~20% nausea at 14 mg | ~44% nausea at 2.4 mg | ~20% nausea at 1 mg |

The weekly injection burden is lower for many patients than the daily fasting administration protocol, and the efficacy evidence in adolescents is far stronger for the injectable forms.

Shared Decision-Making: Talking With Adolescents and Families

A conversation about off-label Rybelsus should cover four domains: the evidence gap, the available alternatives, the practical demands of oral administration, and the monitoring plan.

The 2024 ADA Standards of Care state: "Decisions about medications should involve the patient and family in a shared decision-making process that accounts for the patient's values, preferences, and social context" [11]. This principle applies directly to off-label use in adolescents, where the stakes of inadequate information are higher than in adults.

Adolescents have the cognitive capacity to participate in medical decisions. Including the patient directly, not just the caregiver, improves adherence and long-term treatment engagement. Spending time explaining why the medication must be taken on an empty stomach and what nausea may feel like prepares the patient for the early titration period.